HR+/HER2- Breast Cancer

Oncology

Prevalence

289.8 / 100K

Incidence

30.4 / 100K/yr

14 drugs in development·5 companies·2 clinical trials

Drug Pipeline by Phase

Phase 3(3)

Phase 2(2)

Drug	Company
Ceterizine	ASTRAZENECA PLC (AZN)
Loperamide	ASTRAZENECA PLC (AZN)

Phase 1(2)

Drug	Company
iev407	NOVARTIS AG (NVSEF)
iev407	Novartis AG (NVS)

Phase 1/Phase 2(7)

Drug	Company
avzo-021	AVENUE THERAPEUTICS, INC. (ATXI)
avzo-023	AVENUE THERAPEUTICS, INC. (ATXI)
eci830	Novartis AG (NVS)
eci830	NOVARTIS AG (NVSEF)
erw316	Novartis AG (NVS)
gvv858	Novartis AG (NVS)
GVV858	Novartis AG (NVS)

BioSniper tracks 14 drugs in development for HR+/HER2- Breast Cancer across 5 companies.

There are 2 clinical trials targeting HR+/HER2- Breast Cancer tracked by BioSniper.

The estimated prevalence of HR+/HER2- Breast Cancer is approximately 289.8 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.